Biotech Values

[DewDiligence]

ITMN—I interpret the news as Roche’s agreeing to pay $175M merely to be free and clear of contractual obligations stemming from the 2006 Roche-ITMN partnership for HCV protease inhibitors. Inasmuch as there are newer and better PI’s available, I doubt that Roche will advance ITMN-191 to phase-3.

That ITMN-191 does not have what it takes is old news: e.g. #msg-46797334, #msg-53621981, #msg-53624063.